Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: Evidence and guidance for management

M. John Chapman, Henry N. Ginsberg, Pierre Amarenco, Felicita Andreotti, Jan Borén, Alberico L. Catapano, Olivier S. Descamps, Edward Fisher, Petri T. Kovanen, Jan Albert Kuivenhoven, Philippe Lesnik, Luis Masana, Børge G. Nordestgaard, Kausik K. Ray, Zeljko Reiner, Marja Riitta Taskinen, Lale Tokgözoglu, Anne Tybjærg-Hansen, Gerald F. Watts

Research output: Contribution to journalArticle

Abstract

Even at low-density lipoprotein cholesterol (LDL-C) goal, patients with cardiometabolic abnormalities remain at high risk of cardiovascular events. This paper aims (i) to critically appraise evidence for elevated levels of triglyceride-rich lipoproteins (TRLs) and low levels of high-density lipoprotein cholesterol (HDL-C) as cardiovascular risk factors, and (ii) to advise on therapeutic strategies for management. Current evidence supports a causal association between elevated TRL and their remnants, low HDL-C, and cardiovascular risk. This interpretation is based on mechanistic and genetic studies for TRL and remnants, together with the epidemiological data suggestive of the association for circulating triglycerides and cardiovascular disease. For HDL, epidemiological, mechanistic, and clinical intervention data are consistent with the view that low HDL-C contributes to elevated cardiovascular risk; genetic evidence is unclear however, potentially reflecting the complexity of HDL metabolism. The Panel believes that therapeutic targeting of elevated triglycerides (

Original languageEnglish
Pages (from-to)1345-1361
Number of pages17
JournalEuropean Heart Journal
Volume32
Issue number11
DOIs
Publication statusPublished - Jun 2011

Fingerprint

HDL Cholesterol
Lipoproteins
Triglycerides
Cardiovascular Diseases
LDL Cholesterol
Therapeutics

Keywords

  • Atherogenic dyslipidaemia
  • Atherosclerosis
  • Cardiovascular disease
  • Cholesterol
  • Guidelines
  • High-density lipoprotein cholesterol
  • Remnants
  • Triglyceride-rich lipoproteins
  • Triglycerides

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease : Evidence and guidance for management. / Chapman, M. John; Ginsberg, Henry N.; Amarenco, Pierre; Andreotti, Felicita; Borén, Jan; Catapano, Alberico L.; Descamps, Olivier S.; Fisher, Edward; Kovanen, Petri T.; Kuivenhoven, Jan Albert; Lesnik, Philippe; Masana, Luis; Nordestgaard, Børge G.; Ray, Kausik K.; Reiner, Zeljko; Taskinen, Marja Riitta; Tokgözoglu, Lale; Tybjærg-Hansen, Anne; Watts, Gerald F.

In: European Heart Journal, Vol. 32, No. 11, 06.2011, p. 1345-1361.

Research output: Contribution to journalArticle

Chapman, MJ, Ginsberg, HN, Amarenco, P, Andreotti, F, Borén, J, Catapano, AL, Descamps, OS, Fisher, E, Kovanen, PT, Kuivenhoven, JA, Lesnik, P, Masana, L, Nordestgaard, BG, Ray, KK, Reiner, Z, Taskinen, MR, Tokgözoglu, L, Tybjærg-Hansen, A & Watts, GF 2011, 'Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: Evidence and guidance for management', European Heart Journal, vol. 32, no. 11, pp. 1345-1361. https://doi.org/10.1093/eurheartj/ehr112
Chapman, M. John ; Ginsberg, Henry N. ; Amarenco, Pierre ; Andreotti, Felicita ; Borén, Jan ; Catapano, Alberico L. ; Descamps, Olivier S. ; Fisher, Edward ; Kovanen, Petri T. ; Kuivenhoven, Jan Albert ; Lesnik, Philippe ; Masana, Luis ; Nordestgaard, Børge G. ; Ray, Kausik K. ; Reiner, Zeljko ; Taskinen, Marja Riitta ; Tokgözoglu, Lale ; Tybjærg-Hansen, Anne ; Watts, Gerald F. / Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease : Evidence and guidance for management. In: European Heart Journal. 2011 ; Vol. 32, No. 11. pp. 1345-1361.
@article{f8e50781360c478cbe6850355ece74f2,
title = "Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: Evidence and guidance for management",
abstract = "Even at low-density lipoprotein cholesterol (LDL-C) goal, patients with cardiometabolic abnormalities remain at high risk of cardiovascular events. This paper aims (i) to critically appraise evidence for elevated levels of triglyceride-rich lipoproteins (TRLs) and low levels of high-density lipoprotein cholesterol (HDL-C) as cardiovascular risk factors, and (ii) to advise on therapeutic strategies for management. Current evidence supports a causal association between elevated TRL and their remnants, low HDL-C, and cardiovascular risk. This interpretation is based on mechanistic and genetic studies for TRL and remnants, together with the epidemiological data suggestive of the association for circulating triglycerides and cardiovascular disease. For HDL, epidemiological, mechanistic, and clinical intervention data are consistent with the view that low HDL-C contributes to elevated cardiovascular risk; genetic evidence is unclear however, potentially reflecting the complexity of HDL metabolism. The Panel believes that therapeutic targeting of elevated triglycerides (",
keywords = "Atherogenic dyslipidaemia, Atherosclerosis, Cardiovascular disease, Cholesterol, Guidelines, High-density lipoprotein cholesterol, Remnants, Triglyceride-rich lipoproteins, Triglycerides",
author = "Chapman, {M. John} and Ginsberg, {Henry N.} and Pierre Amarenco and Felicita Andreotti and Jan Bor{\'e}n and Catapano, {Alberico L.} and Descamps, {Olivier S.} and Edward Fisher and Kovanen, {Petri T.} and Kuivenhoven, {Jan Albert} and Philippe Lesnik and Luis Masana and Nordestgaard, {B{\o}rge G.} and Ray, {Kausik K.} and Zeljko Reiner and Taskinen, {Marja Riitta} and Lale Tokg{\"o}zoglu and Anne Tybj{\ae}rg-Hansen and Watts, {Gerald F.}",
year = "2011",
month = "6",
doi = "10.1093/eurheartj/ehr112",
language = "English",
volume = "32",
pages = "1345--1361",
journal = "European Heart Journal",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease

T2 - Evidence and guidance for management

AU - Chapman, M. John

AU - Ginsberg, Henry N.

AU - Amarenco, Pierre

AU - Andreotti, Felicita

AU - Borén, Jan

AU - Catapano, Alberico L.

AU - Descamps, Olivier S.

AU - Fisher, Edward

AU - Kovanen, Petri T.

AU - Kuivenhoven, Jan Albert

AU - Lesnik, Philippe

AU - Masana, Luis

AU - Nordestgaard, Børge G.

AU - Ray, Kausik K.

AU - Reiner, Zeljko

AU - Taskinen, Marja Riitta

AU - Tokgözoglu, Lale

AU - Tybjærg-Hansen, Anne

AU - Watts, Gerald F.

PY - 2011/6

Y1 - 2011/6

N2 - Even at low-density lipoprotein cholesterol (LDL-C) goal, patients with cardiometabolic abnormalities remain at high risk of cardiovascular events. This paper aims (i) to critically appraise evidence for elevated levels of triglyceride-rich lipoproteins (TRLs) and low levels of high-density lipoprotein cholesterol (HDL-C) as cardiovascular risk factors, and (ii) to advise on therapeutic strategies for management. Current evidence supports a causal association between elevated TRL and their remnants, low HDL-C, and cardiovascular risk. This interpretation is based on mechanistic and genetic studies for TRL and remnants, together with the epidemiological data suggestive of the association for circulating triglycerides and cardiovascular disease. For HDL, epidemiological, mechanistic, and clinical intervention data are consistent with the view that low HDL-C contributes to elevated cardiovascular risk; genetic evidence is unclear however, potentially reflecting the complexity of HDL metabolism. The Panel believes that therapeutic targeting of elevated triglycerides (

AB - Even at low-density lipoprotein cholesterol (LDL-C) goal, patients with cardiometabolic abnormalities remain at high risk of cardiovascular events. This paper aims (i) to critically appraise evidence for elevated levels of triglyceride-rich lipoproteins (TRLs) and low levels of high-density lipoprotein cholesterol (HDL-C) as cardiovascular risk factors, and (ii) to advise on therapeutic strategies for management. Current evidence supports a causal association between elevated TRL and their remnants, low HDL-C, and cardiovascular risk. This interpretation is based on mechanistic and genetic studies for TRL and remnants, together with the epidemiological data suggestive of the association for circulating triglycerides and cardiovascular disease. For HDL, epidemiological, mechanistic, and clinical intervention data are consistent with the view that low HDL-C contributes to elevated cardiovascular risk; genetic evidence is unclear however, potentially reflecting the complexity of HDL metabolism. The Panel believes that therapeutic targeting of elevated triglycerides (

KW - Atherogenic dyslipidaemia

KW - Atherosclerosis

KW - Cardiovascular disease

KW - Cholesterol

KW - Guidelines

KW - High-density lipoprotein cholesterol

KW - Remnants

KW - Triglyceride-rich lipoproteins

KW - Triglycerides

UR - http://www.scopus.com/inward/record.url?scp=79958148945&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958148945&partnerID=8YFLogxK

U2 - 10.1093/eurheartj/ehr112

DO - 10.1093/eurheartj/ehr112

M3 - Article

C2 - 21531743

AN - SCOPUS:79958148945

VL - 32

SP - 1345

EP - 1361

JO - European Heart Journal

JF - European Heart Journal

SN - 0195-668X

IS - 11

ER -